Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Most claims made are not supported by the provided Lipitor (June 2009) label excerpts; several include specific pharmacology/timing/population-risk assertions and off-label comparative statements that are not found in the supplied label text.
Category Scores
Accurate Statements
Atorvastatin is affected by grapefruit juice via CYP 3A4 inhibition leading to increased plasma concentrations (especially with >1.2 L/day).
Section 7.2 Grapefruit Juice: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).”
Strong CYP 3A4 inhibitors increase the risk of myopathy during statin treatment.
Section 7.1/7.2 and text shown: “The risk of myopathy during treatment with statins is increased with concurrent administration of… strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole)….”
Elevations of liver transaminases >3 times ULN persisting may require dose reduction or withdrawal of Lipitor.
Section 5.2 Liver Dysfunction: “Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended.”
Unsupported Statements
Benadryl blocks a liver enzyme that helps break down atorvastatin.
No supplied label excerpt mentions diphenhydramine (Benadryl) or any specific enzyme-blocking interaction with atorvastatin.
When the pathway Benadryl blocks is slowed, Lipitor (atorvastatin) levels can rise.
No supplied label excerpt supports a diphenhydramine/atorvastatin pathway effect or plasma concentration increase due to Benadryl.
Rising Lipitor levels increase the chance of muscle pain.
Label excerpted does not tie atorvastatin plasma concentration increases from diphenhydramine to myalgia/muscle pain.
Rising Lipitor levels increase the chance of liver enzyme changes.
No supplied label excerpt links Benadryl-mediated atorvastatin level increases to hepatic enzyme changes.
The interaction between Benadryl and Lipitor is listed in standard drug-interaction databases.
Label excerpts provided do not mention drug-interaction databases or list diphenhydramine as an interacting drug with Lipitor.
Higher statin exposure may worsen leg cramps.
No supplied label excerpt mentions leg cramps or links atorvastatin exposure to leg cramps.
Higher statin exposure may worsen unexplained fatigue.
No supplied label excerpt supports the claim connecting atorvastatin exposure to unexplained fatigue.
Benadryl’s drowsiness and dry-mouth effects remain unchanged when taken together with Lipitor.
No supplied label excerpt addresses Benadryl effects with concurrent atorvastatin, nor any comparative CNS/anticholinergic symptom interaction statement.
Patients over 65 face added risk of confusion or falls when both drugs are taken together.
No supplied label excerpt addresses confusion or falls, nor Benadryl coadministration in older adults.
Both Benadryl and Lipitor have mild central-nervous-system activity.
No supplied label excerpt describes Benadryl CNS activity, nor any statement that Lipitor has mild CNS activity.
Benadryl’s anticholinergic action fades within 24 hours in most adults.
No supplied label excerpt addresses diphenhydramine pharmacodynamics or time course.
The window for elevated Lipitor levels after the last dose of Benadryl is roughly one day.
No supplied label excerpt provides diphenhydramine-related timing for atorvastatin levels.
People with reduced liver or kidney function may clear the drug more slowly.
No supplied label excerpt provided supports this general clearance claim; no renal/hepatic clearance relationship is described in the excerpts to evaluate this statement.
People with reduced liver or kidney function should allow extra time before resuming normal Lipitor dosing.
No supplied label excerpt provides dosing interval guidance based on renal/hepatic impairment in this way.
Non-sedating antihistamines such as loratadine do not block the same liver enzyme as Benadryl.
No supplied label excerpt compares loratadine to diphenhydramine regarding liver enzyme blockade.
Non-sedating antihistamines such as fexofenadine do not block the same liver enzyme as Benadryl.
No supplied label excerpt compares fexofenadine to diphenhydramine regarding liver enzyme blockade.
Loradatine and fexofenadine produce comparable allergy control to Benadryl.
No supplied label excerpt includes efficacy comparison among antihistamines.
Loradatine and fexofenadine have far less risk of amplifying statin side effects.
No supplied label excerpt evaluates loratadine/fexofenadine with statins or provides comparative risk statements.
The key U.S. patents for atorvastatin expired years ago.
No supplied label excerpt discusses patents or regulatory/market status.
Atorvastatin is available from dozens of generic makers due to expired patents.
No supplied label excerpt discusses generic market availability or number of manufacturers.
Lower generic pricing has increased overall statin use.
No supplied label excerpt discusses pricing or prescribing trends.
Drug-interaction screening tools are more important in routine care due to increased statin use.
No supplied label excerpt addresses screening tools or prescribing trends.
Contradictions
Low
AI Statement
Benadryl blocks a liver enzyme that helps break down atorvastatin.
Label Reference
Provided label excerpts do not mention diphenhydramine/Benadryl; therefore this cannot be confirmed as matching the label. No direct contradiction text is present in the excerpts.
Important Omissions
Specific, label-supported atorvastatin contraindications and boxed warnings (e.g., pregnancy contraindication) for the drug-interaction-focused claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide specific interaction mechanism/timing and symptom-risk predictions (muscle pain, liver enzyme changes, confusion/falls) for diphenhydramine/Benadryl that are not supported by the provided label excerpts, which could mislead clinical decision-making relative to label-supported interaction information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Numerous detailed Benadryl–atorvastatin interaction claims (enzyme mechanism, timing, exposure-link to symptoms, older-adult confusion/falls) are not supported by the provided Lipitor prescribing-information excerpts.
Suggested Improvement
Limit interaction statements to label-supported examples (e.g., grapefruit juice CYP3A4 effect; strong CYP3A4 inhibitors increasing myopathy risk; cyclosporine dose limitation) and remove unlabelled claims about diphenhydramine, antihistamine comparisons, patent/generic market assertions, and specific timing or symptom-risk predictions not present in the provided label text.